Candriam S.C.A. decreased its holdings in Synopsys, Inc. (NASDAQ:SNPS - Free Report) by 7.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 76,367 shares of the semiconductor company's stock after selling 5,758 shares during the quarter. Candriam S.C.A.'s holdings in Synopsys were worth $32,750,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cornerstone Planning Group LLC boosted its stake in shares of Synopsys by 275.0% during the 1st quarter. Cornerstone Planning Group LLC now owns 60 shares of the semiconductor company's stock valued at $25,000 after buying an additional 44 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its stake in shares of Synopsys by 441.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 65 shares of the semiconductor company's stock valued at $28,000 after buying an additional 53 shares during the period. Ameriflex Group Inc. acquired a new stake in shares of Synopsys during the 4th quarter valued at $29,000. Cloud Capital Management LLC acquired a new stake in shares of Synopsys during the 1st quarter valued at $36,000. Finally, Meeder Asset Management Inc. boosted its stake in shares of Synopsys by 33.3% during the 1st quarter. Meeder Asset Management Inc. now owns 104 shares of the semiconductor company's stock valued at $45,000 after buying an additional 26 shares during the period. Institutional investors and hedge funds own 85.47% of the company's stock.
Insider Buying and Selling
In other news, CFO Shelagh Glaser sold 7,310 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $485.72, for a total value of $3,550,613.20. Following the transaction, the chief financial officer owned 15,291 shares in the company, valued at approximately $7,427,144.52. This trade represents a 32.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CRO Richard S. Mahoney sold 9,010 shares of the firm's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $471.21, for a total value of $4,245,602.10. Following the completion of the sale, the executive directly owned 1,485 shares of the company's stock, valued at $699,746.85. The trade was a 85.85% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,686 shares of company stock worth $13,001,048. Insiders own 0.62% of the company's stock.
Synopsys Stock Performance
NASDAQ SNPS opened at $612.79 on Wednesday. Synopsys, Inc. has a 1 year low of $365.74 and a 1 year high of $651.73. The company has a debt-to-equity ratio of 1.01, a current ratio of 7.02 and a quick ratio of 6.85. The firm has a market cap of $95.08 billion, a price-to-earnings ratio of 44.24, a PEG ratio of 4.14 and a beta of 1.15. The company has a fifty day moving average price of $563.66 and a 200-day moving average price of $499.14.
Synopsys (NASDAQ:SNPS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 28th. The semiconductor company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $3.40 by $0.27. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.60 billion. Synopsys had a net margin of 34.77% and a return on equity of 17.09%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.00 earnings per share. Synopsys has set its FY 2025 guidance at 15.110-15.190 EPS. Q3 2025 guidance at 3.820-3.87 EPS. As a group, equities research analysts predict that Synopsys, Inc. will post 10.64 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
SNPS has been the subject of a number of research reports. Morgan Stanley reissued an "overweight" rating and set a $715.00 target price (up previously from $540.00) on shares of Synopsys in a research note on Monday, August 11th. Rosenblatt Securities lifted their price objective on shares of Synopsys from $625.00 to $650.00 and gave the company a "buy" rating in a research note on Friday, July 25th. Stifel Nicolaus set a $550.00 price objective on shares of Synopsys in a research note on Monday, April 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $660.00 price objective (up previously from $650.00) on shares of Synopsys in a research note on Tuesday, July 15th. Finally, KeyCorp lifted their price objective on shares of Synopsys from $540.00 to $610.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $630.67.
Read Our Latest Stock Report on SNPS
About Synopsys
(
Free Report)
Synopsys, Inc provides electronic design automation software products used to design and test integrated circuits. It operates in three segments: Design Automation, Design IP, and Software Integrity. The company offers Digital and Custom IC Design solution that provides digital design implementation solutions; Verification solution that offers virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Synopsys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Synopsys wasn't on the list.
While Synopsys currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.